NEW YORK, Jan. 29 - Accelrys has struck a global licensing agreement with AstraZeneca, the informatics firm said on Tuesday.
Terms of the deal call for AstraZeneca researchers to use Accelrys software to understand therapeutic target and to identify and optimize lead compounds, said Accelrys, a Pharmacopeia unit.
Financial details of the agreement were not disclosed.
The arrangement covers scientists at 10 research sites worldwide, including Montreal; Bangalore, India; Södertalje, Lund, and Mölndal, in Sweden; and Wilmington, Del., and Boston, in the US.
All researchers will have access to Accelrys software libraries for modeling and simulation.